CytomX Therapeutics to Present at Upcoming Healthcare Conferences

GlobenewswireRead the rest

CytomX Therapeutics, Inc. (CTMX) Q1 2019 Earnings Call Transcript

Yahoo! FinanceRead the rest

CytomX Therapeutics Announces First Quarter 2019 Financial Results

Yahoo! FinanceRead the rest

CytomX Therapeutics Announces Transition of Chief Financial Officer

GlobenewswireRead the rest

CytomX Therapeutics Announces Transition of Chief Financial Officer

NASDAQRead the rest

CytomX to Present at Upcoming Healthcare Conferences

GlobenewswireRead the rest

CytomX Therapeutics Announces Full-Year 2018 Financial Results

GlobenewswireRead the rest

Big Pharma trims projects — and a potential $1 billion in payments — from collaboration with small Peninsula biotech

Biz Journals San FranciscoRead the rest

Big Pharma trims projects — and a potential $1 billion in payments — from collaboration with small Peninsula biotech

Biz Journals San FranciscoRead the rest

Advancing Immuno-Oncology: The CytomX Story

PharmExecRead the rest

5 Biotech Stocks a Pro Is Buying

Barron’sRead the rest

Medidata Expands Partnership with CytomX Therapeutics to Centralize Management of Regulated and Nonregulated Content

BusinessWireRead the rest

CytomX Announces Third Quarter 2017 Financial Results and Operational Progress

MarketWiredRead the rest

CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors

Globe NewswireRead the rest

Applied BioMath, LLC and CytomX Therapeutics, Inc. Announce a Continuation of their Collaboration for Quantitative Systems Pharmacology Modeling in lmmuno-Oncology

CIsion PR NewswireRead the rest

Amgen and CytomX Therapeutics Announce Partnership for Immuno-Oncology Research

Immuno-Oncology NewsRead the rest

Biotech Giant Amgen Bets $1.5 Billion on Bay Area CytomX’s Cancer Drugs

Pharma LiveRead the rest

Amgen allies with CytomX Therapeutics on immuno-oncology

ZenopaRead the rest

Amgen and CytomX Therapeutics Announce Strategic Collaboration in Immuno-Oncology

Drug Discovery & DevelopmentRead the rest

Amgen announces new T-cell collaboration

Pharma TimesRead the rest

Amgen to Collaborate With CytomX on Cancer Treatment

San Fernando Valley Business journalRead the rest

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

PM LiveRead the rest

CytomX stock rockets 35% after deal with Amgen

MarketWatchRead the rest

What CytomX Gets From Its Huge Amgen Collaboration

24/7 WallStreetRead the rest

Amgen Enters Into an Immuno-Oncology Partnership With CytomX

ZacksRead the rest

CytomX Breaks Out On Mash-Up With Amgen In Immuno-Oncology

Investor’s Business DailyRead the rest

Taking a Fresh Look at CytomX Therapeutics, Inc. (CTMX)

Stock News journalRead the rest

Amgen, CytomX Join in Immuno-Oncology Collaboration

NASDAQRead the rest

CytomX Therapeutics Holding On To Strong Gain In Late-Day Trading

Markets InsiderRead the rest

CytomX in deal that could earn it nearly $1.5 billion

Pharma LetterRead the rest

CytomX Announces Upcoming Trials in Progress Poster Presentations at European Society for Medical Oncology Annual Meeting

Globe NewswireRead the rest

CytomX (CTMX) Announces Second Quarter 2017 Financial Results and Mid-Year Update Webcast Conference Call

BioSpaceRead the rest

Testing underway for CytomX’s immunotherapy drug for cancer patients

Patient DailyRead the rest

CytomX Announces Upcoming Poster Presentation at American Society for Clinical Oncology Annual Meeting

Globe NewswireRead the rest

CytomX Announces Management Team Changes

Globe NewswireRead the rest

CytomX Therapeutics Appoints Marion McCourt to Board of Directors

Globe NewswireRead the rest

Bristol-Myers Squibb’s Motivation Behind CytomX Deal

NASDAQRead the rest

Bristol-Meyer, CytomX extend work against cancer

Salt Lake TribuneRead the rest

Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody™ Therapeutics for the Treatment of Cancer and Other Diseases

Bristol Myers SquibbRead the rest

CytomX Therapeutics Announces Teleconference and Webcast to Provide Corporate Update

globe NewswireRead the rest

CytomX Announces Full-Year 2016 Financial Results

Globe NewswireRead the rest

CytomX Therapeutics to Present at Upcoming Investor Conferences

SAT Press ReleasesRead the rest

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial

Sat Press ReleasesRead the rest

CytomX Announces the First Patient Treated in Phase 1/2 PROCLAIM-072 Trial

Yahoo! FinanceRead the rest

Brief-Applied Biomath Says To Collaborate With CytomX Therapeutics

ReutersRead the rest

Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology

PRNewswireRead the rest

CytomX Announces Fourth Target Selection by Bristol-Myers Squibb Under Strategic Oncology Collaboration

click hereRead the rest

CytomX to Present at the Jefferies 2016 London Healthcare Conference

click hereRead the rest

CytomX Therapeutics Announces Third Quarter 2016 Financial Results and Provides Pipeline Update

click hereRead the rest

CytomX Therapeutics Inc Pipeline Review – Analysis Of Key Players And Enlists All Their Major And Minor Projects 2016

click hereRead the rest

CytomX Therapeutics Appoints John A. Scarlett, M.D., to Board of Directors

click hereRead the rest

CytomX Therapeutics Inc (CTMX) Stock Rating Upgraded by Zacks Investment Research

click hereRead the rest

Top Wall Street Stories: CytomX Therapeutics, Inc. (NASDAQ:CTMX)

click hereRead the rest

Deal Spree for AbbVie Continues with $500 Million Cancer Tie-Up with CytomX

click hereRead the rest

CytomX and AbbVie Announce Strategic Collaboration for Probody Drug Conjugates

click hereRead the rest

CytomX (CTMX), AbbVie (ABBV) Enter Collaboration to Develop Probody Drug Conjugates Against CD71

click hereRead the rest

Tech Coast Angels Invested $13.5 Million into Startup Ecosystem in 2015

Southern California Angel Network Realizes Fourth Highest Investment Total in its 19-Year History

IRVINE, Calif. – February 29, 2016 – Tech Coast Angels (TCA) invested $13.5 million in a total of 58 companies in a diverse mix of industries in 2015.… Read the rest